66 results about "Diabetes in pregnancy" patented technology

The invention provides a synthetic polypeptide of Formula I′:or an amide, an ester or a salt thereof, wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

The invention provides a synthetic polypeptide of Formula I′ (SEQ ID NO: 1):X1-X2-X3-R—X5-X6-X7-X8-X9-X10-X11-X12-X13  Ior an amide, an ester or a salt thereof, wherein X1, X2, X3, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

The invention discloses a composition comprising at least one long chain polyunsaturated fatty acid, at least one probiotic and a mixture of oligosaccharides, said mixture containing at least one of lacto-N-neotetraose (LNnT) and lacto-N-tetraose (LNT), at least one N-acetylated oligosaccharide different from LNnT and LNT, at least one sialylated oligosaccharide and at least one neutral oligosaccharide, for use in increasing insulin sensitivity and / or reducing insulin resistance. This composition optionally further comprises 2′-fucosyllactose (FL). This composition is particularly adapted for use in infants who were born preterm and / or who experienced IUGR, in pregnant women suffering from gestational diabetes and in children, adolescents, and adults suffering from insulin resistance and / or type II diabetes.

A method for measuring blood levels of β cell DNA that is released upon β cell death by using a quantitative probe technology to detect amplified methylated and demethylated forms of the insulin gene DNA, representing normal tissue and β cell specific origin, respectively. Using probes permits the sensitive and specific identification of demethylated insulin DNA patterns that are present only in β cells. The method offers a bioassay for detecting β cell loss in diabetes, useful for screening of prediabetes, monitoring of disease progression, and selection and monitoring of therapies. The technique finds potential use in both Type I and Type II diabetes, as well as gestational diabetes.

The invention belongs to the field of food production, and in particular relates to an enteral nutrition preparation suitable for women with gestational diabetes and its preparation process. The raw materials include: marine animal protein or soybean peptide, laminarin, turtle meat enzymatic hydrolysis powder, olive oil Or tea seed oil, in addition, it also contains active probiotics, amino acids, calcium preparations and fruit and vegetable powder. Its dosage form is powder or emulsion. The invention simultaneously discloses the preparation methods of the two dosage forms of the nutritional preparation. According to the pathological and physical characteristics of women with gestational diabetes and the special nutritional and metabolic needs of mothers and infants, the present invention adopts special pharmacologically active substances and nutritional functional substances for reasonable compounding, enhances the effect of active ingredients, and provides comprehensive health benefits for mothers and infants of women with gestational diabetes. Balanced nutrition can enhance the immune function of the body, reduce pregnancy reactions, prevent the occurrence of gestational diabetes and assist in lowering blood sugar, so as to better ensure the nutrition and health of mothers and infants of women with gestational diabetes.

The present invention relates to a system for predicting the blood glucose level of pregnant individuals, which is characterized in that the system includes an operation module, and the operation module includes a support vector regression model, using the concentration of biomarker substances in the fasting blood samples of pregnant individuals and passing The support vector regression model is used to predict the blood glucose level of pregnant individuals at 1 hour and / or 2 hours after fasting. The invention provides a biomarker and a diagnostic model for the differential diagnosis of gestational diabetes, which can be applied to the early diagnosis or prediction of gestational diabetes, and have great significance for the prevention or treatment of gestational diabetes.

The invention provides application of baicalin in preparation of a drug for treating a fetal neural tube defect caused by gestational diabetes mellitus. Based on a model of a fetus with gestational diabetes mellitus, which is established by a chick embryo, a chick embryo experiment is performed by adopting a traditional Chinese medicine monomer baicalin, a result shows that a certain concentrationof baicalin can be used for effectively relieving the neural tube defect induced by a high glucose environment and effectively relieving poor neural tube cell differentiation, elevation of the levelof homocysteine, reduction of the level of retinoic acid and inhibition on self-renewing of neural stem cells caused by the high glucose environment. According to the application, the application range of the baicalin is enlarged, the application value of the baicalin is improved, and the development of new drugs can be further facilitated, for example, the activity of the baicalin is hopefully improved, or the side effect of the baicalin is reduced by structural modification or transformation by taking the baicalin as a lead compound; the safety drug is provided for preventing the neural tubedefect of the fetus with gestational diabetes mellitus, therefore, the application has good application prospect.